Inhibition of HOX/PBX dimer formation leads to necroptosis in acute myeloid leukemia cells

Lists

Alharbi, Raed, Pandha, Hardev, Simpson, Guy, Pettengell, Ruth, Poterlowicz, Krzysztof, Thompson, Alexander, Harrington, Kevin, El-Tanani, Mohamed and Morgan, Richard ORCID: https://orcid.org/0000-0002-8721-4479 (2017) Inhibition of HOX/PBX dimer formation leads to necroptosis in acute myeloid leukemia cells. Oncotarget, 8 (52). pp. 89566-89579.

[thumbnail of Alharbi Morgan HOX AML.pdf]

Preview

PDF
Alharbi Morgan HOX AML.pdf - Published Version
Available under License Creative Commons Attribution.
Download (4MB) | Preview

Official URL: https://doi.org/10.18632/oncotarget.20023

Abstract

The HOX genes encode a family of transcription factors that have key roles in both development and malignancy. Disrupting the interaction between HOX proteins and their binding partner, PBX, has been shown to cause apoptotic cell death in a range of solid tumors. However, despite HOX proteins playing a particularly significant role in acute myeloid leukemia (AML), the relationship between HOX gene expression and patient survival has not been evaluated (with the exception of HOXA9), and the mechanism by which HOX/PBX inhibition induces cell death in this malignancy is not well understood. In this study, we show that the expression of HOXA5, HOXB2, HOXB4, HOXB9, and HOXC9, but not HOXA9, in primary AML samples is significantly related to survival. Furthermore, the previously described inhibitor of HOX/PBX dimerization, HXR9, is cytotoxic to both AML-derived cell lines and primary AML cells from patients. The mechanism of cell death is not dependent on apoptosis but instead involves a regulated form of necrosis referred to as necroptosis. HXR9-induced necroptosis is enhanced by inhibitors of protein kinase C (PKC) signaling, and HXR9 combined with the PKC inhibitor Ro31 causes a significantly greater reduction in tumor growth compared to either reagent alone.

Item Type:	Article
Identifier:	10.18632/oncotarget.20023
Additional Information:	This study was funded in part through a grant to RA from the Cultural Bureau of the Kingdom of Saudi Arabia.
Keywords:	acute myeloid leukemia, HOX, HXR9, necroptosis, protein kinase C
Subjects:	Natural sciences > Cell and molecular biology
Related URLs:	Organisation Publisher
Depositing User:	Richard Morgan
Date Deposited:	08 Jul 2020 10:05
Last Modified:	04 Nov 2024 11:48
URI:	https://repository.uwl.ac.uk/id/eprint/7101

Downloads

Downloads per month over past year

Actions (login required)

View Item

References

1. Alharbi RA, Pettengell R, Pandha HS, Morgan R. The role of HOX genes in normal hematopoiesis and acute leukemia. Leukemia. 2013; 27: 1000-8. doi: 10.1038/leu.2012.356.

2. Andreeff M, Ruvolo V, Gadgil S, Zeng C, Coombes K, Chen W, Kornblau S, Baron AE, Drabkin HA. HOX expression patterns identify a common signature for favorable AML. Leukemia. 2008; 22: 2041-7. doi: 10.1038/leu.2008.198.

3. Dickson GJ, Liberante FG, Kettyle LM, O’Hagan KA, Finnegan DP, Bullinger L, Geerts D, McMullin MF, Lappin TR, Mills KI, Thompson A. HOXA/PBX3 knockdown impairs growth and sensitizes cytogenetically normal acute myeloid leukemia cells to chemotherapy. Haematologica. 2013; 98: 1216-25. doi: 10.3324/haematol.2012.079012.

4. Morgan R, El-Tanani M, Hunter KD, Harrington KJ, Pandha HS. Targeting HOX/PBX dimers in cancer. Oncotarget. 2017; 8:32322-32331. doi: 10.18632/oncotarget.15971.

5. Plowright L, Harrington KJ, Pandha HS, Morgan R. HOX transcription factors are potential therapeutic targets in non-small-cell lung cancer (targeting HOX genes in lung cancer). Br J Cancer. 2009; 100: 470-5. doi: 10.1038/sj.bjc.6604857.

6. Morgan R, Boxall A, Harrington KJ, Simpson GR, Gillett C, Michael A, Pandha HS. Targeting the HOX/PBX dimer in breast cancer. Breast Cancer Res Treat. 2012; 136: 389-98. doi: 10.1007/s10549-012-2259-2.

7. Morgan R, Boxall A, Harrington KJ, Simpson GR, Michael A, Pandha HS. Targeting HOX transcription factors in prostate cancer. BMC Urol. 2014; 14: 17. doi: 10.1186/1471-2490-14-17.

8. Morgan R, Pirard PM, Shears L, Sohal J, Pettengell R, Pandha HS. Antagonism of HOX/PBX dimer formation blocks the in vivo proliferation of melanoma. Cancer Res. 2007; 67: 5806-13. doi: 10.1158/0008-5472.CAN-06-4231.

9. Daniels TR, Neacato II, Rodriguez JA, Pandha HS, Morgan R, Penichet ML. Disruption of HOX activity leads to cell death that can be enhanced by the interference of iron uptake in malignant B cells. Leukemia. 2010; 24: 1555-65. doi: 10.1038/leu.2010.142.

10. Li Z, Zhang Z, Li Y, Arnovitz S, Chen P, Huang H, Jiang X, Hong GM, Kunjamma RB, Ren H, He C, Wang CZ, Elkahloun AG, et al. PBX3 is an important cofactor of HOXA9 in leukemogenesis. Blood. 2013; 121: 1422-31. doi: 10.1182/blood-2012-07-442004.

11. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002; 30: 207-10.

12. Lecoeur H, de Oliveira-Pinto LM, Gougeon ML. Multiparametric flow cytometric analysis of biochemical and functional events associated with apoptosis and oncosis using the 7-aminoactinomycin D assay. J Immunol Methods. 2002; 265: 81-96.

13. Adrain C, Creagh EM, Martin SJ. Apoptosis-associated release of Smac/DIABLO from mitochondria requires active caspases and is blocked by Bcl-2. EMBO J. 2001; 20: 6627-36. doi: 10.1093/emboj/20.23.6627.

14. Huerta S, Goulet EJ, Huerta-Yepez S, Livingston EH. Screening and detection of apoptosis. J Surg Res. 2007; 139: 143-56. doi: 10.1016/j.jss.2006.07.034.

15. Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Science. 2004; 305: 626-9. doi: 10.1126/science.1099320.

16. Dube H, Selwood D, Malouitre S, Capano M, Simone MI, Crompton M. A mitochondrial-targeted cyclosporin A with high binding affinity for cyclophilin D yields improved cytoprotection of cardiomyocytes. Biochem J. 2012; 441: 901-7. doi: 10.1042/BJ20111301.

17. Hanus J, Zhang H, Wang Z, Liu Q, Zhou Q, Wang S. Induction of necrotic cell death by oxidative stress in retinal pigment epithelial cells. Cell Death Dis. 2013; 4: e965. doi: 10.1038/cddis.2013.478.

18. de Almagro MC, Vucic D. Necroptosis: Pathway diversity and characteristics. Semin Cell Dev Biol. 2015; 39:56-62. doi: 10.1016/j.semcdb.2015.02.002.

19. Okada Y, Jiang Q, Lemieux M, Jeannotte L, Su L, Zhang Y. Leukaemic transformation by CALM-AF10 involves upregulation of Hoxa5 by hDOT1L. Nat Cell Biol. 2006; 8: 1017-24. doi: 10.1038/ncb1464.

20. Huang Y, Wu JZ, Li JY, Xu W. Know the enemy as well as the weapons in hand: the aberrant death pathways and therapeutic agents in chronic lymphocytic leukemia. Am J Cancer Res. 2015; 5: 2361-75.

21. Basit F, Cristofanon S, Fulda S. Obatoclax (GX15-070) triggers necroptosis by promoting the assembly of the necrosome on autophagosomal membranes. Cell Death Differ. 2013; 20: 1161-73. doi: 10.1038/cdd.2013.45.

22. Buac D, Shen M, Schmitt S, Kona FR, Deshmukh R, Zhang Z, Neslund-Dudas C, Mitra B, Dou QP. From bortezomib to other inhibitors of the proteasome and beyond. Curr Pharm Des. 2013; 19: 4025-38.

23. Steinhart L, Belz K, Fulda S. Smac mimetic and demethylating agents synergistically trigger cell death in acute myeloid leukemia cells and overcome apoptosis resistance by inducing necroptosis. Cell Death Dis. 2013; 4: e802. doi: 10.1038/cddis.2013.320.

24. Horita H, Frankel AE, Thorburn A. Acute myeloid leukemia-targeted toxin activates both apoptotic and necroptotic death mechanisms. PLoS One. 2008; 3: e3909. doi: 10.1371/journal.pone.0003909.

25. Morgan R, Plowright L, Harrington KJ, Michael A, Pandha HS. Targeting HOX and PBX transcription factors in ovarian cancer. BMC Cancer. 2010; 10: 89. doi: 10.1186/1471-2407-10-89.

26. Kazi JU, Kabir NN, Ronnstrand L. Protein kinase C (PKC) as a drug target in chronic lymphocytic leukemia. Med Oncol. 2013; 30: 757. doi: 10.1007/s12032-013-0757-7.

27. Kilpatrick LE, Sun S, Korchak HM. Selective regulation by delta-PKC and PI 3-kinase in the assembly of the antiapoptotic TNFR-1 signaling complex in neutrophils. Am J Physiol Cell Physiol. 2004; 287: C633-42. doi: 10.1152/ajpcell.00486.2003.

28. Nikoletopoulou V, Markaki M, Palikaras K, Tavernarakis N. Crosstalk between apoptosis, necrosis and autophagy. Biochim Biophys Acta. 2013; 1833: 3448-59. doi: 10.1016/j.bbamcr.2013.06.001.

29. Karimian A, Ahmadi Y, Yousefi B. Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage. DNA Repair (Amst). 2016; 42: 63-71. doi: 10.1016/j.dnarep.2016.04.008.

30. Gaidzik VI, Bullinger L, Schlenk RF, Zimmermann AS, Rock J, Paschka P, Corbacioglu A, Krauter J, Schlegelberger B, Ganser A, Spath D, Kundgen A, Schmidt-Wolf IG, et al. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. J Clin Oncol. 2011; 29: 1364-72. doi: 10.1200/JCO.2010.30.7926.

31. Huber W, Carey VJ, Gentleman R, Anders S, Carlson M, Carvalho BS, Bravo HC, Davis S, Gatto L, Girke T, Gottardo R, Hahne F, Hansen KD, et al. Orchestrating high-throughput genomic analysis with Bioconductor. Nat Methods. 2015; 12: 115-21. doi: 10.1038/nmeth.3252.

32. Koeffler HP, Golde DW. Acute myelogenous leukemia: a human cell line responsive to colony-stimulating activity. Science. 1978; 200: 1153-4. doi: 10.1126/science.306682.

33. Martin P, Papayannopoulou T. HEL cells: a new human erythroleukemia cell line with spontaneous and induced globin expression. Science. 1982; 216: 1233-5. doi: 10.1126/science.6177045.

34. Collins SJ, Ruscetti FW, Gallagher RE, Gallo RC. Terminal differentiation of human promyelocytic leukemia cells induced by dimethyl sulfoxide and other polar compounds. Proceedings of the National Academy of Sciences of the United States of America. 1978; 75: 2458-62. doi: 10.1073/pnas.75.5.2458.

35. Morgan R, Pirard PM, Shears L, Sohal J, Pettengell R, Pandha HS. Antagonism of HOX/PBX dimer formation blocks the in vivo proliferation of melanoma. Cancer Research. 2007; 67: 5806-13. doi: 10.1158/0008-5472.can-06-4231.

36. Li Y, Johnson N, Capano M, Edwards M, Crompton M. Cyclophilin-D promotes the mitochondrial permeability transition but has opposite effects on apoptosis and necrosis. Biochem J. 2004; 383: 101-9. doi: 10.1042/bj20040669.

37. Basso E, Fante L, Fowlkes J, Petronilli V, Forte MA, Bernardi P. Properties of the Permeability Transition Pore in Mitochondria Devoid of Cyclophilin D. Journal of Biological Chemistry. 2005; 280: 18558-61. doi: 10.1074/jbc.C500089200.

38. Dube H, Selwood D, Malouitre S, Capano M, Simone MI, Crompton M. A mitochondrial-targeted cyclosporin A with high binding affinity for cyclophilin D yields improved cytoprotection of cardiomyocytes. Biochemical Journal. 2012; 441: 901-7. doi: 10.1042/bj20111301.

39. Degterev A, Hitomi J, Germscheid M, Ch’en IL, Korkina O, Teng X, Abbott D, Cuny GD, Yuan C, Wagner G, Hedrick SM, Gerber SA, Lugovskoy A, et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nature Chemical Biology. 2008; 4: 313-21. doi: 10.1038/nchembio.83.

40. Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N, Cuny GD, Mitchison TJ, Moskowitz MA, Yuan J. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol. 2005; 1: 112-9.

41. Nieminen AL, Saylor AK, Herman B, Lemasters JJ. ATP depletion rather than mitochondrial depolarization mediates hepatocyte killing after metabolic inhibition. American Journal of Physiology. 1994; 267: C67-C74.

42. Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene. 2007; 26: 3279-90.

43. Lambeth JD. NOX enzymes and the biology of reactive oxygen. Nat Rev Immunol. 2004; 4: 181-9.

44. Park SE, Song JD, Kim KM, Park YM, Kim ND, Yoo YH, Park YC. Diphenyleneiodonium induces ROS-independent p53 expression and apoptosis in human RPE cells. FEBS letters. 2007; 581: 180-6.

45. Liu XL, Van Vleet T, Schnellmann RG. The role of calpain in oncotic cell death. Annual Review of Pharmacology and Toxicology. 2004; 44: 349-70. doi: 10.1146/annurev.pharmtox.44.101802.121804.

46. Rushworth SA, MacEwan DJ. HO-1 underlies resistance of AML cells to TNF-induced apoptosis. Blood. 2008; 111: 3793-801. doi: 10.1182/blood-2007-07-104042.

47. Chou TC. Relationships between inhibition Constants and Fractional Inhibition in Enzyme-Catalyzed Reactions with Different Numbers of Reactants, Different Reaction Mechanisms, and Different Types and Mechanisms of Inhibition. Molecular Pharmacology. 1974; 10: 235-47.

48. Chou TC. (1991). The median-effect principle and the combination index for quantitation of synergism and antagonism.

Tools

CORE (COnnecting REpositories)

The University of West London

Inhibition of HOX/PBX dimer formation leads to necroptosis in acute myeloid leukemia cells

Abstract

Downloads

Actions (login required)

Menu